Search

Displaying results 4541 - 4550 of 5923 in total
  1. Drug

    Gridegalutamide

    go.drugbank.com/drugs/DB21593
    Investigational

    Gridegalutamide has a monoisotopic molecular weight of 818.32 Da.

  2. Drug

    Docirbrutinib

    go.drugbank.com/drugs/DB21606
    Investigational

    Docirbrutinib has a monoisotopic molecular weight of 578.24 Da.

  3. Drug

    Tamuzimod

    go.drugbank.com/drugs/DB21621
    Investigational

    Tamuzimod has a monoisotopic molecular weight of 545.0 Da.

  4. Drug

    Lomedeucitinib

    go.drugbank.com/drugs/DB21649
    Investigational

    Lomedeucitinib has a monoisotopic molecular weight of 419.15 Da.

  5. Drug

    Bimokalner

    go.drugbank.com/drugs/DB21717
    Investigational

    Bimokalner has a monoisotopic molecular weight of 355.1 Da.

  6. Drug

    Ocadusertib

    go.drugbank.com/drugs/DB21732
    Investigational

    Ocadusertib has a monoisotopic molecular weight of 459.19 Da.

  7. Drug

    Mefloquine

    go.drugbank.com/drugs/DB00358
    Approved

    [A226838] This drug has been the subject of widespread controversy due to concerns regarding neurotoxic effects; product information warns of potential serious neuropsychiatric effects.[A226838,L8953]

    Categories: P-glycoprotein inhibitors, P-glycoprotein substratesSynonyms: (DL-ERYTHRO-.ALPHA.-2-PIPERIDYL-2,8-BIS(TRIFLUOROMETHYL)-4-QUINOLINEMETHANOL
  8. Drug

    Chlorpropamide

    go.drugbank.com/drugs/DB00672
    ApprovedWithdrawn

    Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesSynonyms: 1-(p-chlorobenzenesulfonyl)-3-propylurea, 1-(p-chlorophenylsulfonyl)-3-propylurea
  9. Drug

    Droxidopa

    go.drugbank.com/drugs/DB06262
    ApprovedInvestigational

    The racaemic form (dl-threo-3,4-dihydroxyphenylserine) has also been used, and has been investigated in the treatment of orthostatic hypotension.

  10. Drug

    Elacridar

    go.drugbank.com/drugs/DB04881
    Investigational

    In many cases, the appearance of multidrug resistance in cancer is due to a change in expression of protein inhibitors. As of August 2007 elacridar was not listed on GSK's product pipeline.

    Categories: P-glycoprotein inhibitors